Viral Adjuvants Enhance Mucosal Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccination methods face challenges in inducing robust immune responses, particularly at mucosal surfaces, where many pathogens enter the body, and existing adjuvants may not effectively enhance immune responses against immunogens not presented by the virus.
Innovation Solution
The use of virus particles, specifically alphavirus and Venezuelan Equine Encephalitis (VEE) viral adjuvants, which do not express the immunogen, to enhance both mucosal and systemic immune responses by acting as immunostimulatory agents, even when the immunogen is not presented by the virus, through administration of the immunogen and the viral adjuvant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If virus particles are used as vaccine vectors to deliver immunogen, then immune response is induced, but the adjuvant effect is limited to immunogens presented by the virus
Solution Approach 1:
The invention separates the vaccine delivery function from the adjuvant function. Virus particles are used solely as adjuvants to stimulate immune responses, while the immunogen is delivered separately through other means (such as subunit vaccines, mRNA, or other vector systems). This segmentation allows the viral adjuvant to enhance immunity against any immunogen without requiring the immunogen to be packaged or presented by the virus itself.
Solution Approach 2:
The viral adjuvant is designed to provide universal immune stimulation that can enhance responses to diverse immunogens. By using virus particles that do not present the immunogen but instead provide general pathogen-associated molecular patterns (PAMPs) and immune activation signals, the system achieves broad applicability across different vaccine types and targets, making the adjuvant effect independent of specific immunogen-virus matching.
2Reliability
If traditional adjuvants are used to enhance immune responses, then immune activation is achieved, but effectiveness at mucosal surfaces is insufficient
Solution Approach 1:
Virus particles serve as an intermediary that bridges the gap between traditional adjuvants and mucosal immune protection. These viral adjuvants can target and activate immune cells at mucosal surfaces through mechanisms such as direct infection of mucosal-associated lymphoid tissue, stimulation of secretory IgA production, and activation of mucosal-associated invariant T cells (MAIT cells), thereby providing protection at the critical barrier where pathogens first enter the body.
Solution Approach 2:
The invention changes the parameters of adjuvant action by using virus particles that can replicate to varying degrees (from replication-competent to replication-defective), allowing tuning of the immune response intensity and duration. Different viral vectors can be selected or engineered to provide appropriate levels of immune stimulation for different mucosal vaccine applications, optimizing protection against specific pathogens while maintaining safety.
Data Source
AI summary
The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.